Fundraising Fox
/Companies
Sign in

BioAmp Diagnostics

San Carlos, US · 3 known investors

Find your way into BioAmp Diagnostics

Each arrow is one introduction. Sign up to fill in the first one.

236 people can intro you to Tara

Ask Alice Zhang to introduce you to Tara DeBoer

You →Alice · together at California Life Sciences (CLS) →Tara

Sign up to find every way you can get introduced to BioAmp Diagnostics

  • Your email: who you already know at BioAmp Diagnostics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the BioAmp Diagnostics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

BioAmp Diagnostics develops a chemistry-based rapid diagnostic pipeline (DETECT: Dual-Enzyme Trigger-Enabled Cascade Technology) that delivers infection results in minutes to guide antibiotic prescribing, initially targeting complicated urinary tract infections. The technology is intended to help physicians select the correct antibiotic and support efforts to combat antibiotic resistance.

BiotechDigital HealthMedical Devices

Founders & leadership

TDTara DeBoer
Tara DeBoerChief Executive OfficerTara DeBoer is a research scientist with background in developing strategies in biology and medicine who leads BioAmp Diagnostics as CEO, which develops rapid diagnostic technology to enable faster and more accurate antibiotic selection.
ARAngel Resendez
Angel ResendezDirector of Chemistry - Small Molecule Discovery, CSIO

Investors · 3

Blue Bear Ventureslisted by Blue Bear VenturesBerkeley · $100K – $400K

How we know: Blue Bear Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Illumina AcceleratorreportedSan Diego

How we know: funding news · Not right? Tell us

Frequently asked questions

What does BioAmp Diagnostics do?
BioAmp Diagnostics develops a chemistry-based rapid diagnostic pipeline (DETECT: Dual-Enzyme Trigger-Enabled Cascade Technology) that delivers infection results in minutes to guide antibiotic prescribing, initially targeting complicated urinary tract infections. The technology is intended to help physicians select the correct antibiotic and support efforts to combat antibiotic resistance.
Who are BioAmp Diagnostics's investors?
BioAmp Diagnostics's investors include Berkeley Angel Network, Blue Bear Ventures, Illumina Accelerator.
Where is BioAmp Diagnostics headquartered?
BioAmp Diagnostics is headquartered in San Carlos, US.